Table 3: Patient's characteristics among positive and negative anti-IFX antibodies.

Positive anti-IFX antibodiesNegative anti-IFX antibodies value

Disease duration, mean, and months 0.306
IFX treatment duration, mean, and months 0.511
DAS28 at flare and mean 0.189
DAS28 after 2 months and mean 0.006
csDMARD association and nr (%)390.028

Differences between patient's characteristics were tested by Student’s -test or chi-square test.
IFX: infliximab; csDMARD: conventional synthetic disease modifying antirheumatic drug.